Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepivacaine vs Bupivacaine for TKA Spinal Anesthesia
NCT06291727Phase 4Completed
- Sponsor
- Prisma Health
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mepivacaine in knee osteoarthritis (OA) (2 arms), sponsored by Prisma Health. Primary endpoint: Same day discharge rate at 24 hours. Started Feb 2024; status: completed.
02
Drugs
mepivacaine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06291727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291727.